Clareo Health | FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine
ASAT (SGOT), ALAT (SGPT) ≤ 2.5 x ULN or ≤ 5 x ULN if liver metastases found
Bilirubin ≤ 1.5 x ULN (patients drained by retrograde technique are includable), creatinine \< 120 μmol/L, or MDRD creatinine clearance \> 60 mL/min
Women of childbearing age must have a negative pregnancy test (β HCG) before starting treatment
Women of childbearing age as well as men (who have sexual intercourse with women of childbearing age) must agree to use effective contraception without interruption for the duration of treatment and 6 months after the administration of the last treatment dose
Patient affiliated to the social security scheme
Patient information and signature of informed consent
You may not be if
\- Other types of pancreatic tumours, especially endocrine or acinar cell tumours
Ampulloma
Presence of meningeal or cerebral metastases, bone metastases
Gilbert's syndrome
Presence of neuropathy\> grade 1 according to NCIC-CTC 4.0
Contraindications specific to the studied treatments
History of chronic diarrhoea or inflammatory disease of the colon or rectum, or of unresolved occlusion or sub-occlusion for which symptomatic treatment is being administered
Other concomitant cancer or history of cancer during the 5 years, with the exception of a carcinoma in situ of the cervix or basal cell or squamous cell carcinoma, considered cured
Significant history of heart or respiratory disease, including any history of interstitial pneumonia
Patient already included in another clinical trial with an experimental molecule
Women who are breast-feeding
Persons deprived of liberty or under guardianship
Unable to submit to medical monitoring during the trial due to geographical, social or psychological reasons
